{"url":"https://newsforagent.com/news/2026-11-11/alvotech-nine-month-revenue-guidance","markdown_url":"https://newsforagent.com/news/2026-11-11/alvotech-nine-month-revenue-guidance.md","title":"Alvotech Revenue Falls 23% to $323.4 Million in First Nine Months","headline":"Alvotech Posts $323.4 Million Nine-Month Revenue, Keeps 2026 Guidance Toward Low End","description":"Alvotech reported $323.4 million in adjusted revenue for the nine months to September 30, 2026, down 23%, and kept full-year guidance of $650-700 million.","section":"Earnings & Results","published_at":"2026-11-11T21:43:13+00:00","modified_at":"2026-11-11T21:43:13+00:00","author":"News Desk","key_takeaways":["Alvotech's adjusted total revenue fell 23% to $323.4 million for the nine months to September 30, 2026, from $420.0 million a year earlier.","Adjusted EBITDA rose to $78.3 million from $68.0 million, while the reported cash balance fell to $61.5 million from $172.4 million at December 31, 2025.","Alvotech kept full-year 2026 guidance of $650-700 million in revenue and $180-220 million in EBITDA, now expecting the lower end."],"companies":[{"name":"Alvotech","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00000ty/alvotech","website":"http://www.alvotech.com"},{"name":"Fujifilm","is_primary":false,"profile_url":"https://akta.pro/company-profiles/0004h7u/fujifilm","website":"http://www.fujifilm.com"},{"name":"Lotus Pharmaceuticals, Inc.","is_primary":false,"profile_url":"https://akta.pro/company-profiles/005o5i3/lotus-pharmaceuticals-inc","website":"https://lotuspharmaceuticalsusa.com"}],"source":{"publisher":"Stock Titan","title":"Alvotech 9M Earnings: Revenue Falls 23% to $323M","url":"https://www.stocktitan.net/news/ALVO/alvotech-announces-financial-results-for-the-nine-months-to-1ih06zto19q3.html"},"other_sources":[],"tags":["Earnings & Results","Alvotech","Fujifilm","Lotus Pharmaceuticals, Inc."],"body_markdown":"[Alvotech](https://akta.pro/company-profiles/00000ty/alvotech) reported adjusted total revenue of $323.4 million for the nine months to September 30, 2026, down 23% from $420.0 million a year earlier, and kept its full-year 2026 revenue guidance of $650-700 million while saying it now expects the lower end. [Stock Titan](https://www.stocktitan.net/news/ALVO/alvotech-announces-financial-results-for-the-nine-months-to-1ih06zto19q3.html) published the results on November 11, 2026.\n\n## Alvotech's Revenue Mix and Simlandi Approvals\n\nProduct and service revenue was $164.2 million, down 30.8% from $237.4 million, and license and other revenue was $158.9 million, down 12.9% from $182.4 million. Gross margin was 54% against 59% a year earlier, while adjusted EBITDA rose to $78.3 million from $68.0 million. The reported cash balance at the end of the period was $61.5 million, compared with $172.4 million on December 31, 2025.\n\nAlvotech is a Reykjavik-based biotechnology company founded in 2013 that develops and manufactures biosimilar monoclonal antibodies for immunology, ophthalmology, oncology and bone health, selling them through partners including Teva, Sandoz and Advanz Pharma. The company said the FDA approved a new manufacturing process for its Humira biosimilar Simlandi at its Reykjavik facility that more than doubles output per batch, and approved drug substance production for Simlandi in a second production suite there.\n\nLisa Graver, Chief Executive Officer, said: \"Our commercial performance strengthened in the third quarter, with product and service revenue reaching $58 million, up 6% sequentially and 78% year over year.\" Graver said the company's priority is \"to translate this progress into planned product deliveries in the fourth quarter.\" The company said its partnerships with LOTTE Biologics and Fujifilm strengthen its future manufacturing network. [Fujifilm](https://akta.pro/company-profiles/0004h7u/fujifilm) reported second-quarter operating profit of ¥90 billion, up 8% year over year and beating analyst estimates, Investing.com reported on November 9, 2026.\n\n## Alvotech's 2026 Capital Raise and Regeneron Settlement\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Alvotech closed a $165 million capital raise in June 2026 through an underwritten public offering of $98 million and a concurrent private placement of $67 million at $3.75 per share, to fund biosimilar development, commercialization and potential debt refinancing. The same records show a December 2025 settlement and license agreement with Regeneron enabling a US launch of AVT06, its Eylea biosimilar, in the fourth quarter of 2026, contingent on FDA approval.\n\n## Alvotech's Path From FDA Setback to Eylea Filing\n\nIn November 2025, Alvotech received an FDA Complete Response Letter rejecting the BLA for AVT05, its Simponi biosimilar, citing manufacturing facility deficiencies at the Reykjavik site, Stock Titan reported. In October 2026, Alvotech and Advanz Pharma filed an EMA application for a biosimilar to Eylea in the 8 mg strength, the first such application worldwide, according to GlobeNewswire. Alvotech and LOTTE Biologics announced a long-term manufacturing partnership in October 2026, with LOTTE producing drug substance for multiple antibody biosimilars at its Syracuse, New York facility, Stock Titan reported.\n\n## Alvotech's Fourth-Quarter Deliveries and March Results\n\nAlvotech said it remains focused on executing planned product deliveries in the fourth quarter as production and commercial supply ramp up. The company scheduled its fourth-quarter and full-year 2026 results for March 10, 2027, with an earnings call on March 11, 2027.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}